Leukemia & Lymphoma

Ibrutinib Yields Durable Responses in CLL

Monotherapy with the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib was well tolerated and produced durable responses in a phase Ib/II, open-label, multicenter study of 85 patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Leukemia & Lymphoma

Long-term outcomes of patients treated for pediatric acute lymphoblastic leukemia (ALL) with modern treatment protocols are good, with an overall low risk for serious long-term side effects.

The FDA has approved the drug belinostat to treat patients with relapsed or refractory peripheral T-cell lymphoma.

Measuring changes in levels of BCR-ABL in patients with chronic myeloid leukemia (CML) can help predict treatment outcomes and disease progression, according to a new study.

Researchers have identified Down syndrome as a risk factor for infection-related mortality among pediatric patients with acute lymphoblastic leukemia.

A novel inhibitor of CD19 was well tolerated and showed promising activity in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma, according to a phase I study.

A pooled analysis of three prospective trials showed that post-induction therapy PET-CT scans are highly predictive of progression-free and overall survival in follicular lymphoma patients.

A phase II trial of the selective spleen tyrosine kinase (Syk) inhibitor GS-9973 showed substantial biologic activity in patients with chronic lymphocytic leukemia (CLL).


Subscribe to Leukemia & Lymphoma on [sitename]
Please Wait 20 seconds or click here to close